Moderna and Oxford have launched INTERCEPT‑Lynch, the first mRNA cancer prevention vaccine trial for individuals with Lynch syndrome. Authorized by the UK MHRA, the Phase 1/2 study of mRNA‑4194 will assess safety, immune responses, and dosing, marking a major step toward precision cancer prevention.
Written By: Kirti Kumbar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized a Phase 1/2 clinical study of mRNA-4194, Moderna’s investigational cancer prevention vaccine for individuals with Lynch syndrome. The program, known as INTERCEPT-Lynch, marks Moderna’s first effort to use mRNA technology to prevent cancer before it develops rather than treat established disease.
Sponsored by the University of Oxford and funded by Moderna, the trial will begin dosing participants in summer 2026. An initial dose-escalation phase will evaluate safety and immunogenicity, followed by a planned expansion phase in 2027 across multiple centers in the United Kingdom.
Genetic Basis and Unmet Need
Lynch syndrome is the most common inherited cancer predisposition syndrome, affecting approximately one in 300 people. The condition results from inherited mutations in DNA mismatch repair genes, including MLH1, MSH2, MSH6, PMS2, and EPCAM. These defects allow DNA errors to accumulate over time, substantially increasing lifetime cancer risk, which can reach up to 80%.
Individuals with Lynch syndrome face elevated risks of multiple malignancies, including colorectal, endometrial, ovarian, gastric, and prostate cancers. Current management relies largely on intensive cancer surveillance, low-dose aspirin, and preventive surgery in selected patients, highlighting the need for more targeted prevention strategies.
Mechanism of Action
mRNA-4194 uses Moderna’s mRNA platform to generate immune responses against molecular targets associated with the earliest stages of cancer development. Researchers hope the vaccine can train the immune system to recognize and eliminate precancerous cells before they progress to invasive disease.
The Phase 1/2 study will assess safety, characterize immune responses, and identify an optimal dose for future clinical development.
Strategic Collaboration and UK Footprint
The INTERCEPT-Lynch program is part of a broader scientific collaboration between Moderna and the University of Oxford focused on advancing precision cancer prevention. The study also reflects Moderna’s 10-year strategic partnership with the UK government, established in 2022 to strengthen domestic mRNA research, development, and manufacturing capabilities.
Since the partnership began, more than 20 clinical trials have been conducted across 135 UK sites involving over 14,500 participants. The collaboration has also supported the development of the Moderna Innovation and Technology Centre in Oxfordshire, reinforcing the UK’s role as a growing hub for mRNA innovation.
Clinical Implications
David Berman, MD, PhD, Moderna’s Chief Development Officer, said the authorization supports efforts to shift cancer care toward prevention by applying mRNA technology earlier in the disease process.
Lead investigator Professor David Church of the University of Oxford emphasized that people with Lynch syndrome face a substantial lifetime cancer burden and often develop cancer at younger ages than the general population. He noted that the study will evaluate whether immune recognition of early cancer-associated changes can reduce future cancer risk.
More broadly, investigators view the trial as an early test of whether immune intervention at the precancer stage can alter cancer risk in genetically susceptible individuals. Success would extend the application of mRNA technology beyond infectious diseases and therapeutic cancer vaccines into preventive oncology.
Path Forward
If successful, mRNA-4194 could establish a new category of preventive cancer vaccines for individuals with inherited cancer susceptibility syndromes. Findings from INTERCEPT-Lynch will help determine whether the approach advances into larger studies evaluating its ability to reduce cancer incidence.
The program also represents an important step in the emerging field of precision prevention, where therapies are deployed before disease develops in high-risk populations. Early clinical results will provide the first indication of whether mRNA-based immune strategies can play a role in reducing inherited cancer risk.
Reference
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.